Adalimumab biosimilar ABP 501 is equally effective and safe in long-term management of inflammatory bowel diseases patients when used as first biologic treatment or as replace of the ADA originator for a non-medical reason

Adalimumab biosimilar ABP 501 is equally effective and safe in long-term management of inflammatory bowel diseases patients when used as first biologic treatment or as replace of the ADA originator for a non-medical reason

ObjectiveBiosimilars represent a new opportunity for inflammatory bowel disease (IBD) treatment and economic sustainability of therapies. This study aimed to evaluate the efficacy and long-term safety of the adalimumab biosimilar ABP 501 in biologic-naïve vs. biologic-switched IBD patients.MethodsA...

Full description

Bibliographic Details
Main Authors: Giammarco Mocci, Arianna Cingolani, Giorgia Orrù, Carla Felice, Francesca Maria Onidi, Gianmarco Lombardi, Davide Checchin, Raffaele Colucci, Laurino Grossi, Antonio Ferronato, Chiara Rocchi, Marta Ascolani, Paolo Usai Satta, Lucia Fanini, Stefano Pilati, Antonio Tursi
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Gastroenterology
Subjects:
adalimumab
ABP 501
biosimilar
Crohn’s disease
ulcerative colitis
Online Access:https://www.frontiersin.org/articles/10.3389/fgstr.2023.1218228/full

Internet

https://www.frontiersin.org/articles/10.3389/fgstr.2023.1218228/full

Similar Items